1 completed, 1 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow trospium chloride: new trials by email Literature Review of trospium chloride trials Research Report on trospium chloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia Xanomeline and trospium chloride (KarXT) - SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder | Phase 1 / Phase 2 | Recruiting | New York State Psychiatric Institute | 12 | 2026-07-01 | 2026-07-14 |
| A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia Xanomeline and Trospium Chloride Capsules, Placebo Capsules - Schizophrenia | Phase 2 | Completed | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 182 | 2018-09-18 | 2020-10-26 |
Schizophrenia (1)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company (1) · New York State Psychiatric Institute (1)
United States (2)
Joshua T Kantrowitz, MD (1) · Ragy Girgis, MD (1) · Stephen Brannan, MD (1)
PMID 33626254, PMID 34700212, PMID 35552528, PMID 36414626, PMID 40047530, PMID 40145363, PMID 40212458, PMID 40215379